Literature DB >> 26247878

Cerebrospinal fluid concentrations of tenofovir and emtricitabine in the setting of HIV-1 protease inhibitor-based regimens.

Cecile D Lahiri1, Kedria Reed-Walker2, Anandi N Sheth1, Edward P Acosta2, Aswani Vunnava1, Ighovwerha Ofotokun1.   

Abstract

Entities:  

Keywords:  HIV/AIDS; central nervous system; clinical pharmacology

Mesh：

Substances：

Year:  2015        PMID： 26247878      PMCID： PMC4744587          DOI： 10.1002/jcph.612

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  19 in total

1.  Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir.

Authors:  Tomoki Imaoka; Hiroyuki Kusuhara; Masashi Adachi; John D Schuetz; Kenji Takeuchi; Yuichi Sugiyama
Journal:  Mol Pharmacol       Date:  2006-11-16       Impact factor: 4.436

Review 2.  The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters.

Authors:  Olena Kis; Kevin Robillard; Gary N Y Chan; Reina Bendayan
Journal:  Trends Pharmacol Sci       Date:  2009-12-11       Impact factor: 14.819

3.  Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteers.

Authors:  Lawrence S Lee; Gaik H Soon; Ping Shen; Eu-Leong Yong; Charles Flexner; Paul Pham
Journal:  Antivir Ther       Date:  2010

4.  Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir.

Authors:  Brookie M Best; Scott L Letendre; Peter Koopmans; Steven S Rossi; David B Clifford; Ann C Collier; Benjamin B Gelman; Christina M Marra; Justin C McArthur; J Allen McCutchan; Susan Morgello; David M Simpson; Edmund V Capparelli; Ronald J Ellis; Igor Grant
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-01       Impact factor: 3.731

5.  Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group.

Authors:  R J Ellis; R Deutsch; R K Heaton; T D Marcotte; J A McCutchan; J A Nelson; I Abramson; L J Thal; J H Atkinson; M R Wallace; I Grant
Journal:  Arch Neurol       Date:  1997-04

6.  Emtricitabine: Inhibitor and substrate of multidrug resistance associated protein.

Authors:  Laurence Bousquet; Alain Pruvost; Nathalie Didier; Robert Farinotti; Aloïse Mabondzo
Journal:  Eur J Pharm Sci       Date:  2008-07-18       Impact factor: 4.384

7.  Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.

Authors:  Maarten T Huisman; Johan W Smit; Kristel M L Crommentuyn; Noam Zelcer; Hugh R Wiltshire; Jos H Beijnen; Alfred H Schinkel
Journal:  AIDS       Date:  2002-11-22       Impact factor: 4.177

Review 8.  Effects of antiretroviral therapy on cognitive impairment.

Authors:  Kevin J Liner; Colin D Hall; Kevin R Robertson
Journal:  Curr HIV/AIDS Rep       Date:  2008-05       Impact factor: 5.071

9.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01

10.  P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir.

Authors:  Omar Janneh; Tariq Anwar; Christof Jungbauer; Stefan Kopp; Saye H Khoo; David J Back; Peter Chiba
Journal:  Antivir Ther       Date:  2009
View more
  12 in total

1.  Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid.

Authors:  Andrew J Ocque; Colleen E Hagler; Gene D Morse; Scott L Letendre; Qing Ma
Journal:  J Pharm Biomed Anal       Date:  2018-04-23       Impact factor: 3.935

2.  Morphine counteracts the antiviral effect of antiretroviral drugs and causes upregulation of p62/SQSTM1 and histone-modifying enzymes in HIV-infected astrocytes.

Authors:  Myosotys Rodriguez; Jessica Lapierre; Chet Raj Ojha; Shashank Pawitwar; Mohan Kumar Muthu Karuppan; Fatah Kashanchi; Nazira El-Hage
Journal:  J Neurovirol       Date:  2019-02-11       Impact factor: 2.643

3.  Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid.

Authors:  Qing Ma; Andrew J Ocque; Gene D Morse; Chelsea Sanders; Alina Burgi; Susan J Little; Scott L Letendre
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

4.  Risk for Speech and Language Impairments in Preschool Age HIV-exposed Uninfected Children With In Utero Combination Antiretroviral Exposure.

Authors:  Mabel L Rice; Jonathan S Russell; Toni Frederick; Murli Purswani; Paige L Williams; George K Siberry; Sean M Redmond; Howard J Hoffman; Tzy-Jyun Yao
Journal:  Pediatr Infect Dis J       Date:  2018-07       Impact factor: 2.129

5.  Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir.

Authors:  Xiaomei I Liu; Jeremiah D Momper; Natella Rakhmanina; John N van den Anker; Dionna J Green; Gilbert J Burckart; Brookie M Best; Mark Mirochnick; Edmund V Capparelli; André Dallmann
Journal:  J Clin Pharmacol       Date:  2019-09-06       Impact factor: 3.126

6.  Important roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs.

Authors:  Mengbi Yang; Xin Xu
Journal:  Expert Opin Drug Metab Toxicol       Date:  2022-09-09       Impact factor: 4.936

Review 7.  Pharmacology of HIV Cure: Site of Action.

Authors:  Aaron S Devanathan; Mackenzie L Cottrell
Journal:  Clin Pharmacol Ther       Date:  2021-03-05       Impact factor: 6.875

8.  Targeting Beclin1 as an Adjunctive Therapy against HIV Using Mannosylated Polyethylenimine Nanoparticles.

Authors:  Myosotys Rodriguez; Yemmy Soler; Mohan Kumar Muthu Karuppan; Yuling Zhao; Elena V Batrakova; Nazira El-Hage
Journal:  Pharmaceutics       Date:  2021-02-06       Impact factor: 6.321

9.  Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid.

Authors:  Eric H Decloedt; Phumla Z Sinxadi; Lubbe Wiesner; John A Joska; David W Haas; Gary Maartens
Journal:  South Afr J HIV Med       Date:  2021-04-28       Impact factor: 2.744

10.  Intramuscular and subcutaneous administration of antiretroviral drugs, compared with oral, enhances delivery to lymphoid tissues in BALB/c mice.

Authors:  Shetty Ravi Dyavar; Sushil Kumar; Nagsen Gautam; Anthony T Podany; Lee C Winchester; Jonathan A Weinhold; Timothy M Mykris; Palanisamy Nallasamy; Yazen Alnouti; Courtney V Fletcher
Journal:  J Antimicrob Chemother       Date:  2021-09-15       Impact factor: 5.758
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.